Sirnaomics Aims to Move Wound-Healing Drug into Phase I Next Year

Doing so, however, will require the company to secure additional funding, and it is currently evaluating its options, a company official said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.